Sophia Genetics expands relationship with Gustave Roussy

written by CAP TODAY
October 20, 2023

October 2023—Sophia Genetics announced the expansion of its relationship with Gustave Roussy in which the cancer center will use the Sophia DDM digital analytics platform for all relevant samples, including those related to solid tumors and hematologic and hereditary cancers. Gustave Roussy, which has two campuses in France, began working with the cloud-native software company in 2017. Sophia Genetics is located in France and Boston.

Visiopharm, Boston Cell Standards to develop IHC technology

written by CAP TODAY
October 20, 2023

October 2023—Visiopharm and Boston Cell Standards announced they are partnering to integrate immunohistochemistry calibration standards with image analysis software for quality assurance. The joint technology solution will enable laboratories to meet key provisions of regulatory changes proposed in an editorial published in *Archives of Pathology & Laboratory Medicine*.

Roche launches vertical transportation for patient lab samples

written by CAP TODAY
October 20, 2023

Oct. 18, 2023—Roche announced the U.S. launch of its Cobas Connection Modules Vertical, designed to help low-, mid-, and high-volume laboratories optimize space, productivity, and patient care.

The CCM Vertical includes elevator units, overhead conveyors, and overhead turn units that integrate with Roche's other CCM solutions. It transports patient samples up, down, and across and between rooms; around doorways, emergency exits, and walkways; and through walls, ceilings, and floors.

"The CCM Vertical is the only laboratory conveyor system in the U.S. that moves samples up and down without reducing overall track speed, throughput, or turnaround times," Brad Moore, president and CEO of Roche Diagnostics North America, said in a press statement. "The CCM system is about quality, flexibility, and efficiency—helping labs of all sizes meet today's challenges to increase testing capacity, accelerate results, overcome staffing shortages, and reduce errors."

The first CCM Vertical implementation in the United States is scheduled to go live at Vanderbilt University Medical Center in early 2024.

BioMérieux announces CE mark for Vidas TBI test

written by CAP TODAY
October 20, 2023

Oct. 17, 2023—BioMérieux announced it has received the CE mark for its Vidas TBI (GFAP, UCH-L1), a test to support the assessment of patients who have mild traumatic brain injury. The blood test measures the concentration of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-

L1 (UCH-L1), two brain biomarkers that are released into the bloodstream during the first hour following a brain injury. The test aims to fill a gap in patient screening methods by ruling out acute intracranial lesions and helping to determine if a CT scan is necessary.

Vidas TBI has a testing window of up to 12 hours and can be run on Vidas 3 and Vidas Kube immunoassay analyzers. Commercial launch of the test is planned in selected European, North African, and South American markets in the last quarter of this year and in 2024–2025 for the rest of the world.

Test GTxcel GAM

written by CAP TODAY
October 20, 2023

OGT, Intelliseq partner to provide NGS analysis and reporting

written by CAP TODAY
October 20, 2023

Oct. 12, 2023—OGT announced a partnership with Intelliseq, a genome informatics company and provider of next-generation sequencing analysis solutions.

Bio SB launches TintoStainer Plus automatic IHC stainer

written by CAP TODAY
October 20, 2023

Oct. 9, 2023—Bio SB has launched a fully automated immunohistochemistry platform for deparaffinization and antigen retrieval and staining.

---

mTuitive introduces Insight database

written by CAP TODAY
October 20, 2023

Oct. 6, 2023—MTuitive has introduced its mTuitive Insight, a consolidated database designed to give a comprehensive view of cancer data and tie together structured data from any health care IT system.

FDA clears Nova Prime Plus for microcapillary sample mode

written by CAP TODAY
October 20, 2023

Oct. 5, 2023—Nova Biomedical announced that the FDA has granted 510(k) clearance for a microcapillary sample mode on the company's Stat Profile Prime Plus critical care blood gas analyzer. It is available as a standard feature.

Comanche drug for preeclampsia gets fast track designation

written by CAP TODAY
October 20, 2023

September 2023—Comanche Biopharma announced it has received fast track designation from the FDA for its CBP-4888 as a novel small interfering ribonucleic acid (siRNA) therapy for preeclampsia. CBP-4888 is a fixed-dose combination of two chemically synthesized, lipid-conjugated siRNA duplex oligonucleotides, siRNA-2283 and siRNA-2519, targeting two soluble fms-like tyrosine kinase–1 (sFLT1) mRNA isoforms. Fast track is designed to facilitate the development and expedite the review process of drugs to treat serious conditions and fill an unmet medical need.